Formerly known as ComChem Technologies and renamed as Semafore Pharmaceuticals in 2004, the firm's proprietary research is focused to using combinatorial chemistry technology to find compounds capable of selectively deliver of anticancer agents to tumors. Semafore is a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway, one of the most promising target pathways for multiple disorders, including the companyâs focus--cancer Semafore Pharmaceuticals, Inc. discovers and develops clinical-stage drugs. PI3 kinase/PTEN cellular controls angiogenesis, apoptosis, migration, invasion, metastasis, and survival. Pproducts include SF1126, a PI3K Inhibitor Conjugate for prostate, breast, ovarian, renal, multiple myeloma, and other solid and hematological cancers, as well as cancers metastasized to bone; PI3K small-molecule inhibitors for cancer, inflammation, and other indications; and PTEN Inhibitors & Agonists for cell protection and therapeutic angiogenesis
